Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOSH101 in Androgenetic Alopecia
NCT00471510Phase 2Unknown
- Sponsor
- Neosil
- Start
- May 2007
- Primary completion
- Feb 2008
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of neosh101 in androgenetic alopecia (AGA) (4 arms), sponsored by Neosil. Primary endpoint: Hair density, hair growth rate, hair diameter at 28 weeks. Status: unknown.
02
Drugs
neosh101
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT00471510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471510.